Zelos Becoms Azelon; Restructures To Close A Series A
This article was originally published in The Pink Sheet Daily
Executive Summary
The osteoporosis drug company has revamped its focus and brought in new investors as it pushes forward with its nasal spray for osteoporosis.
You may also be interested in...
Recapitalization Becomes A Better Alternative In A Weak Economy
Biotechs face the new reality that recapitalization may be the only route to new funding when development plans go off track due to the constricted capital markets.
Recapitalization Becomes A Better Alternative In A Weak Economy
Biotechs face the new reality that recapitalization may be the only route to new funding when development plans go off track due to the constricted capital markets.
After D-mab: Next-Generation Osteoporosis Drugs Focus On Building Bone
Anti-resorptive denosumab is what Amgen is counting on for its future growth. But denosumab may be the last of the current generation of drugs which prevent bone breakdown: newer drugs in development help build bone.